Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is testing a new treatment for people with multiple myeloma, which is a type of cancer. They will be given a drug called isatuximab with another drug called carfilzomib, and sometimes with other drugs like dexamethasone and lenalidomide. Isatuximab and carfilzomib may stop cancer cells from growing and spreading, and the other drugs may kill the cells or stop them from dividing. This new treatment may be better than other treatments for people with multiple myeloma that has come back or hasn't responded to previous treatment.
This study is testing a new treatment for people with multiple myeloma, which is a type of cancer. They will be given a drug called isatuximab with another drug called carfilzomib, and sometimes with other drugs like dexamethasone and lenalidomide. Isatuximab and carfilzomib may stop cancer cells from growing and spreading, and the other drugs may kill the cells or stop them from dividing. This new treatment may be better than other treatments for people with multiple myeloma that has come back or hasn't responded to previous treatment.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving isatuximab and carfilzomib with or without dexamethasone and lenalidomide may be a better treatment for patients with multiple myeloma.
This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving isatuximab and carfilzomib with or without dexamethasone and lenalidomide may be a better treatment for patients with multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: